AARDEX Group is dedicated to advancing clinical research and improving patient outcomes through our innovative solutions for measuring and managing medication adherence. We recognize that clinical trials are complex endeavors requiring multiple stakeholders' involvement, each with unique expertise and capabilities. That's why we have built an ecosystem of partners who share our vision and commitment to improving patient outcomes through clinical trial success.
Our ecosystem includes some of the most prominent and respected names in the industry, including CMOs, CROs, EDC, IRT, DCT vendors, and several industry-leading adherence packaging and device developers. By collaborating with these partners, AARDEX Group is leading the way in streamlining the approach to measuring and managing adherence in various clinical trial settings, including site-based, hybrid, and decentralized.
Our partners bring a wealth of knowledge and expertise to the table. By working together, we can develop innovative solutions that address the unique challenges of clinical trial adherence management. Our collective efforts are transforming how medication adherence is measured and managed, resulting in more accurate data and improved patient outcomes.
At AARDEX Group, we are proud to be part of a network of partners that is making a significant impact on the field of clinical research. Our commitment to advancing clinical trial success through collaboration and innovation is unwavering, and we look forward to continuing to work with our partners to improve the lives of patients everywhere.
WEBINAR WITH MERCK & BIOGEN
Mitigating the Risk of Poor Adherence in Trials
Watch this live recording with adherence experts from Merck & Biogen to learn about their approach to mitigating the risk of poor adherence in trials.
FROM THE AARDEX GROUP BLOG
We are thrilled to feature expert insights from Bernard Vrijens, a world-renowned expert on medication adherence. Taking medication as prescribed is crucial to achieving optimal health outcomes, yet non-adherence is a prevalent issue. Bernard Vrijens' extensive research and experience in the field provide invaluable insights into the factors that contribute to medication non-adherence and effective strategies to address them. His contributions to our medication adherence blog offer actionable advice and evidence-based recommendations to improve medication adherence and ultimately, patient outcomes.
It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,
In this article, Dr. Vrijens shares his thoughts on the need for dose optimization in the interests of balancing safety and efficacy. How we use language has a huge bearing on the meaning we convey. Take the word ‘overdose’, for
In this article, Dr. Bernard Vrijens discusses the importance of medication adherence data in clinical trials and why medication adherence should be a calculation, not an estimation. The world is today collecting a mind-blowing amount of data. Indeed, IDC calculates that about
In this article, our Scientific Lead, Bernard Vrijens, discusses the influence of medication non-adherence on ROI in clinical trials. Get ready for an insightful read! Fraught with risk yet pivotal to the future success of a drug candidate, clinical trials
This action, if finalized, will require applicants to create a new type of medication guide, referred to as Patient Medication Information (PMI). In this article, our Scientific Lead, Bernard Vrijens, unpacks the proposals and questions whether more is needed to
Adherence specialists join multi-stakeholder CancerX initiative to improve long-term pathways for cancer patients and meet the challenge of oral treatments. Liege, Belgium- July 18, 2023: Adherence specialist AARDEX Group is proud to announce it is a founding member of the CancerX initiative, bringing